NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
Provided By GlobeNewswire
Last update: Nov 18, 2024
– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 –
– Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 –
Read more at globenewswire.comNASDAQ:NAMSW (4/29/2025, 1:31:59 PM)
8.2
-0.32 (-3.76%)
NASDAQ:NAMS (4/29/2025, 2:56:58 PM)
18.22
+0.39 (+2.19%)
Find more stocks in the Stock Screener
